Catalyst Pharmaceutical (CPRX) reported 122.71millioninrevenueforthequarterendedJune2024,representingayear−over−yearincreaseof23.20.56 for the same period compares to 0.33ayearago.ThereportedrevenuecomparestotheZacksConsensusEstimateof111.76 million, representing a surprise of +9.80%. The company delivered an EPS surprise of +33.33%, with the consensus EPS estimate being $0.42. While investors closely watch year-over-year changes in headline numbers -- revenue and ...